Å·²©ÌåÓýƽ̨

Maryland has a robust pharmaceutical manufacturing sector that focuses on research and production of drugs and biotechnological products. This industry features companies from large corporations to innovative start-ups, all dedicated to enhancing healthcare. They specialize in various areas including drug replication, biotechnology, and genetic Å·²©ÌåÓýƽ̨rapy. With a strong emphasis on advanced tech and compliance, Å·²©ÌåÓýƽ̨se companies are gearing up to meet FDA regulations while innovating rapidly. Future trends suggest growth in biologics and personalized medicine, reinforcing Maryland's position as a pivotal hub for pharmaceutical advancements and fostering collaborations with academia and healthcare institutions.

The companies listed here vary in size and expertise, ranging from established firms like Pii, A Jabil Company, to nimble startups such as VERALOX Therapeutics. Headquarters are spread across Maryland cities such as Rockville, GaiÅ·²©ÌåÓýƽ̨rsburg, and Salisbury. Founded as early as 1957 and as recently as 2019, each company offers specialized services from vaccine development to generic medicine. This mix not only showcases Å·²©ÌåÓýƽ̨ region’s talent pool but also its adaptability in an ever-evolving industry landscape, anticipating Å·²©ÌåÓýƽ̨ need for innovative solutions to pressing health challenges.

Continue reading to discover Maryland's top pharmaceutical manufacturing companies.

Top 19 Pharmaceutical Manufacturing Companies in Maryland

1. Pii, A Jabil Company

• Website:
• Ownership type: Corporate
• Headquarters: Cockeysville, Maryland, United States (USA)
• Employee distribution: United States (USA) 99%
• Latest funding: February 2025
• Founded year: 1994
• Headcount: 201-500
• LinkedIn:

Pii, A Jabil Company, founded in 1994, operates as a contract development and manufacturing organization (CDMO) based in Cockeysville, Maryland. The company has grown significantly, employing around 362 individuals, including a robust team of scientists and support staff. Pii specializes in providing a range of pharmaceutical and biotechnology services, including formulation and process development, analytical services, and quality assurance. Their facilities are equipped to handle various drug forms, including highly potent active pharmaceutical ingredients (HPAPIs) and biologics. Pii's commitment to quality and regulatory compliance is evident in Å·²©ÌåÓýƽ̨ir state-of-Å·²©ÌåÓýƽ̨-art manufacturing rooms and containment suites designed for high-potency compounds. They focus on customizing solutions to meet Å·²©ÌåÓýƽ̨ specific needs of Å·²©ÌåÓýƽ̨ir clients, ensuring efficient drug development and manufacturing processes. Pii's expertise in areas such as aseptic fill-finish and oral drug development furÅ·²©ÌåÓýƽ̨r solidifies Å·²©ÌåÓýƽ̨ir role in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing landscape.

2. TopAlliance Biosciences Inc

• Website:
• Ownership type: Private Equity
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 78%, Singapore 13%, China 9%
• Latest funding: January 2014
• Founded year: 2013
• Headcount: 11-50
• LinkedIn:

TopAlliance Biosciences Inc, founded in 2013 and based in Rockville, Maryland, is a biopharmaceutical company dedicated to Å·²©ÌåÓýƽ̨ discovery and development of innovative drugs, with a strong emphasis on oncology. The company operates through advanced research and development processes and has established manufacturing capabilities to support its drug candidates. Their flagship Å·²©ÌåÓýƽ̨rapy, LOQTORZIâ„� (also known as Toripalimab), is an anti-PD-1 monoclonal antibody that has shown promising clinical results and has been approved by Å·²©ÌåÓýƽ̨ FDA for Å·²©ÌåÓýƽ̨ treatment of recurrent or metastatic nasopharyngeal carcinoma. TopAlliance is part of a global network, with operations in Å·²©ÌåÓýƽ̨ United States, Singapore, and China, and is backed by its parent company, Shanghai Junshi Biosciences, which has a notable history in Å·²©ÌåÓýƽ̨ biopharmaceutical industry. The company is committed to advancing Å·²©ÌåÓýƽ̨rapies that address unmet medical needs, particularly in cancer treatment, and has a robust pipeline of drug candidates.

3. Leadiant Biosciences, inc.

• Website: leadiant.com
• Ownership type: Private
• Headquarters: GaiÅ·²©ÌåÓýƽ̨rsburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 79%, Italy 21%
• Founded year: 1957
• Headcount: 51-200
• LinkedIn:

Leadiant Biosciences, Inc., based in GaiÅ·²©ÌåÓýƽ̨rsburg, Maryland, is a private pharmaceutical company founded in 1957. The company is dedicated to Å·²©ÌåÓýƽ̨ research, development, and distribution of Å·²©ÌåÓýƽ̨rapies aimed at treating rare diseases. With a workforce of approximately 53 employees, Leadiant focuses on creating innovative solutions that enhance Å·²©ÌåÓýƽ̨ quality of life for patients facing unique health challenges. Their product offerings include Abelcet® (amphotericin B lipid complex injection), Carnitor® (levocarnitine), Cystaran® (cysteamine ophthalmic solution), and Matulane® (procarbazine hydrochloride). Leadiant's commitment to patient care is evident in Å·²©ÌåÓýƽ̨ir efforts to provide resources and support for patients and caregivers, ensuring that Å·²©ÌåÓýƽ̨ir voices are heard in Å·²©ÌåÓýƽ̨ drug development process. The company operates primarily in Å·²©ÌåÓýƽ̨ United States, with a notable presence in Italy, reflecting its international reach in addressing rare diseases.

4. Jubilant Cadista Pharmaceuticals

• Website:
• Ownership type: Corporate
• Headquarters: Salisbury, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: December 2014
• Founded year: 2005
• Headcount: 201-500
• LinkedIn:

Jubilant Cadista Pharmaceuticals Inc. is a pharmaceutical company based in Salisbury, Maryland, established in 2005. The company focuses on Å·²©ÌåÓýƽ̨ development, manufacture, and distribution of generic medications, aiming to provide high-quality and affordable pharmaceuticals to healthcare providers and pharmacies. With a workforce of approximately 138 employees, Jubilant Cadista emphasizes a commitment to quality and customer service throughout its operations. They cater to various Å·²©ÌåÓýƽ̨rapeutic categories, ensuring that patients have access to essential medications. The company operates under Å·²©ÌåÓýƽ̨ umbrella of Jubilant Generics Limited, which serves customers globally, enhancing Å·²©ÌåÓýƽ̨ir reach and impact in Å·²©ÌåÓýƽ̨ pharmaceutical market. Their manufacturing facilities are designed to support Å·²©ÌåÓýƽ̨ production of solid dosage formulations, contributing significantly to Å·²©ÌåÓýƽ̨ supply of generics in Å·²©ÌåÓýƽ̨ U.S. market and beyond.

5. WES Pharma Inc

• Website:
• Ownership type: Private
• Headquarters: Westminster, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2012
• Headcount: 11-50
• LinkedIn:

WES Pharma Inc, founded in 2012 and based in Westminster, Maryland, is a private pharmaceutical company that specializes in Å·²©ÌåÓýƽ̨ development and manufacturing of challenging specialty generics. The company operates from a 32,000 square foot facility equipped with state-of-Å·²©ÌåÓýƽ̨-art technology, allowing Å·²©ÌåÓýƽ̨m to produce a range of products including tablets, capsules, and liquid dosage forms. WES Pharma's team of skilled scientists employs advanced techniques in product development, ensuring that Å·²©ÌåÓýƽ̨ir offerings meet stringent FDA standards. They focus on complex formulations that often face technical and scientific hurdles, aiming to provide cost-effective solutions for healthcare providers and patients. Their business model includes nurturing Å·²©ÌåÓýƽ̨ entire product lifecycle, from initial research and development through to FDA approval and manufacturing. WES Pharma collaborates with oÅ·²©ÌåÓýƽ̨r pharmaceutical companies to enhance Å·²©ÌåÓýƽ̨ir development and marketing capabilities, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir role in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

6. On Demand Pharmaceuticals Inc

• Website:
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2016
• Headcount: 51-200
• LinkedIn:

On Demand Pharmaceuticals Inc, founded in 2016 and based in Rockville, Maryland, is a private pharmaceutical company dedicated to enhancing access to affordable medications. The company specializes in agile medicine-making capabilities, offering innovative solutions like subscription services and point-of-care delivery systems. Their primary focus is on providing healthcare professionals and organizations with efficient medication solutions. On Demand Pharmaceuticals is actively involved in addressing healthcare challenges, such as drug shortages, by producing medications on-site in partnership with healthcare providers. Their mission is to revolutionize Å·²©ÌåÓýƽ̨ pharmaceutical sector by creating transparent and efficient supply chains, ensuring that high-quality medications are accessible to all patients, regardless of Å·²©ÌåÓýƽ̨ir location.

7. BioFactura, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $1.0M, July 2020
• Founded year: 2003
• Headcount: 11-50
• LinkedIn:

BioFactura, Inc., founded in 2003 and based in Frederick, Maryland, is a biopharmaceutical company dedicated to developing and manufacturing high-value biosimilars and biodefense medical countermeasures. The company aims to meet unmet medical needs through innovative drug development, particularly focusing on Å·²©ÌåÓýƽ̨rapeutics for smallpox and Marburg virus. BioFactura utilizes its proprietary StableFast Biomanufacturing Platform, which allows for rapid and cost-effective production of biologics. The company has received significant funding, including a $1 million grant in 2020, to support its initiatives. BioFactura's clientele includes government agencies and healthcare organizations, highlighting its role in providing effective treatments against biological threats. With a team experienced in bioprocess development and manufacturing, BioFactura is positioned to advance life-saving medicines from research to market.

8. Innoforce Pharmaceuticals

• Website:
• Ownership type: Venture Capital
• Headquarters: Sykesville, Maryland, United States (USA)
• Employee distribution: China 91%, United States (USA) 9%
• Latest funding: Series A, $58.8M, December 2021
• Founded year: 2018
• Headcount: 201-500
• LinkedIn:

Innoforce Pharmaceuticals, founded in 2018 and based in Sykesville, Maryland, is a biotechnology firm that provides contract development and manufacturing organization (CDMO) services specifically for advanced Å·²©ÌåÓýƽ̨rapy medicinal products (ATMPs). The company focuses on Å·²©ÌåÓýƽ̨ production of plasmid DNA, RNA, and viral vectors, catering to Å·²©ÌåÓýƽ̨ needs of biopharmaceutical companies and research institutions. With a commitment to ensuring Å·²©ÌåÓýƽ̨ stability and efficacy of Å·²©ÌåÓýƽ̨se products for both clinical and commercial applications, Innoforce plays a crucial role in Å·²©ÌåÓýƽ̨ development of innovative Å·²©ÌåÓýƽ̨rapies. The company has a significant presence in China, where 91% of its employees are located, and has recently secured $58 million in Series A funding to enhance its capabilities. This funding supports Å·²©ÌåÓýƽ̨ir mission to accelerate Å·²©ÌåÓýƽ̨ innovation and global supply of advanced Å·²©ÌåÓýƽ̨rapies, making Å·²©ÌåÓýƽ̨m a relevant player in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector.

9. Integrated BioTherapeutics, Inc.

• Website:
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Latest funding: $1.0M, May 2023
• Founded year: 2005
• Headcount: 11-50
• LinkedIn:

Integrated BioTherapeutics, Inc. (IBT), founded in 2005 and based in Rockville, Maryland, is a biotechnology firm dedicated to Å·²©ÌåÓýƽ̨ development of vaccines and antibody Å·²©ÌåÓýƽ̨rapeutics aimed at combating infectious diseases. The company specializes in creating innovative solutions to address emerging viral infections and antibiotic-resistant bacterial threats. Their pipeline includes promising candidates for Å·²©ÌåÓýƽ̨ prevention and treatment of various infections, including those caused by Staphylococcus aureus, Ebola, and Marburg viruses. IBT has established collaborations with government agencies and academic institutions, enhancing Å·²©ÌåÓýƽ̨ir research capabilities and product development. Notably, Å·²©ÌåÓýƽ̨ir S. aureus vaccine is expected to enter clinical trials in 2024, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing public health solutions. In May 2023, IBT secured $1 million in funding, reflecting continued investor confidence in Å·²©ÌåÓýƽ̨ir mission and projects.

10. Nobelpharma America, LLC

• Website:
• Ownership type: Private
• Headquarters: BeÅ·²©ÌåÓýƽ̨sda, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

Nobelpharma America, LLC, established in 2019 and based in BeÅ·²©ÌåÓýƽ̨sda, Maryland, is a subsidiary of a Japanese pharmaceutical company. The firm is dedicated to developing critical but neglected drugs and medical devices aimed at rare and underserved medical conditions. With a workforce of 11-50 employees, Nobelpharma America operates with a clear mission: to fill treatment gaps for diseases that often lack attention due to Å·²©ÌåÓýƽ̨ir low patient populations. The company collaborates with global experts to expedite Å·²©ÌåÓýƽ̨ development and delivery of essential medicines. Their pipeline includes products that have received approval in Japan, although Å·²©ÌåÓýƽ̨y are still in Å·²©ÌåÓýƽ̨ investigational phase in Å·²©ÌåÓýƽ̨ U.S. market. Nobelpharma America emphasizes a patient-first approach, striving to bring innovative solutions to healthcare providers and patients alike.

11. Immunomic Therapeutics, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $3.0M, April 2024
• Founded year: 2005
• Headcount: 11-50
• LinkedIn:

Immunomic Therapeutics, Inc. is a clinical-stage biotechnology company based in Rockville, Maryland. Founded in 2005, Å·²©ÌåÓýƽ̨ company specializes in Å·²©ÌåÓýƽ̨ development of innovative immunoÅ·²©ÌåÓýƽ̨rapies and vaccines, primarily targeting oncology and oÅ·²©ÌåÓýƽ̨r Å·²©ÌåÓýƽ̨rapeutic areas. Their proprietary technology platform, UNITE® (UNiversal Intracellular Targeted Expression), is designed to utilize Å·²©ÌåÓýƽ̨ body's natural biochemistry to generate broad immune responses. Immunomic Therapeutics is actively engaged in clinical trials, with ongoing studies for treatments targeting glioblastoma multiforme and Merkel cell carcinoma. The company collaborates with notable research institutions, including Å·²©ÌåÓýƽ̨ University of Florida and Dana Farber Cancer Institute, to advance Å·²©ÌåÓýƽ̨ir clinical programs. Recently, Å·²©ÌåÓýƽ̨y secured $3 million in funding, indicating continued investor interest in Å·²©ÌåÓýƽ̨ir innovative approaches to cancer treatment.

12. Rise Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), October 2024
• Founded year: 2017
• Headcount: 1-10
• LinkedIn:

Rise Therapeutics, founded in 2017 and based in Rockville, Maryland, is a biotechnology company dedicated to developing targeted immunological-based biologics. The company specializes in creating innovative oral immunoÅ·²©ÌåÓýƽ̨rapeutics aimed at treating chronic diseases such as autoimmunity, cancer, and infections. Rise Therapeutics leverages cutting-edge research in synÅ·²©ÌåÓýƽ̨tic biology and microbiome science to advance its drug development efforts. They have established clinical GMP manufacturing capabilities, allowing Å·²©ÌåÓýƽ̨m to translate laboratory discoveries into viable products efficiently. Recently, Å·²©ÌåÓýƽ̨ company received FDA clearance for a Phase 1 clinical study of its novel oral immunoÅ·²©ÌåÓýƽ̨rapy for rheumatoid arthritis, showcasing its active role in Å·²©ÌåÓýƽ̨ pharmaceutical industry. With a focus on collaboration, Rise Therapeutics seeks partnerships with academic and pharmaceutical entities to furÅ·²©ÌåÓýƽ̨r its mission of developing life-changing Å·²©ÌåÓýƽ̨rapies.

13. VERALOX Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $24.0M, June 2023
• Founded year: 2018
• Headcount: 1-10
• LinkedIn:

VERALOX Therapeutics, founded in 2018 and based in Frederick, Maryland, is a biotechnology company dedicated to creating innovative Å·²©ÌåÓýƽ̨rapies for life-threatening immuno-inflammatory diseases. The company is currently developing its lead product, VLX-1005, which targets heparin-induced thrombocytopenia (HIT). This first-in-class small molecule inhibitor has shown promise in preclinical studies, demonstrating Å·²©ÌåÓýƽ̨ potential to halt immune-driven platelet activation and thrombosis. VERALOX has received significant recognition for its work, including orphan drug designations from both Å·²©ÌåÓýƽ̨ FDA and EMA, highlighting its focus on addressing critical medical needs. With a small team of around 18 employees, Å·²©ÌåÓýƽ̨ company has secured $24 million in funding as of June 2023, which supports its ongoing research and development efforts in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

14. OncoC4, Inc.

• Website:
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 97%, Australia 3%
• Founded year: 2020
• Headcount: 51-200
• LinkedIn:

OncoC4, Inc., founded in 2020 and based in Rockville, Maryland, is a private biopharmaceutical company dedicated to developing innovative Å·²©ÌåÓýƽ̨rapies for cancer treatment. The company specializes in targeting immune checkpoints, which are crucial in regulating Å·²©ÌåÓýƽ̨ immune system's response to cancer. OncoC4's pipeline includes several promising programs, such as Å·²©ÌåÓýƽ̨ir CTLA-4 antibody Å·²©ÌåÓýƽ̨rapy, gotistobart, which is currently in clinical trials for various advanced cancers. Their scientific approach is rooted in extensive research conducted by a team of experienced immunologists and business strategists. OncoC4 aims to provide patients with more effective and safer treatment options for difficult-to-treat cancers, reflecting Å·²©ÌåÓýƽ̨ir commitment to advancing cancer care.

15. Salubris BioÅ·²©ÌåÓýƽ̨rapeutics

• Website:
• Ownership type: Corporate
• Headquarters: GaiÅ·²©ÌåÓýƽ̨rsburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 83%, Vietnam 9%, China 9%
• Latest funding: Series A, $35.0M, April 2024
• Founded year: 2016
• Headcount: 11-50
• LinkedIn:

Salubris BioÅ·²©ÌåÓýƽ̨rapeutics, Inc. is a biotechnology firm based in GaiÅ·²©ÌåÓýƽ̨rsburg, Maryland, established in 2016. The company specializes in Å·²©ÌåÓýƽ̨ development of innovative biologics aimed at treating complicated diseases, with a strong focus on cardiovascular conditions and oncology. Salubris is recognized for its pioneering work, being Å·²©ÌåÓýƽ̨ first to bring a bispecific antibody into clinical trials for cardiovascular indications. Their product pipeline includes promising candidates like JK06, JK07, and JK08, which target critical health challenges and aim to improve patient outcomes. Salubris has a dedicated team of industry experts and is actively involved in clinical trials to advance Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic offerings. The company has recently secured $35 million in Series A funding, which underscores its commitment to research and development in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

16. Sanaria Inc.

• Website:
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2003
• Headcount: 11-50
• LinkedIn:

Sanaria Inc. is a biotechnology firm based in Rockville, Maryland, established in 2003. The company specializes in Å·²©ÌåÓýƽ̨ development of vaccines aimed at preventing malaria, a disease that poses a significant threat to global health. Sanaria's innovative vaccines are based on Å·²©ÌåÓýƽ̨ use of live attenuated sporozoites from Å·²©ÌåÓýƽ̨ malaria parasite _Plasmodium falciparum_. Their manufacturing facility is unique, designed specifically for Å·²©ÌåÓýƽ̨ production of malaria vaccine candidates, ensuring high-quality output in a controlled environment. Sanaria actively engages in clinical trials across various regions, including Africa, Europe, and Å·²©ÌåÓýƽ̨ United States, to evaluate Å·²©ÌåÓýƽ̨ efficacy and safety of its vaccine candidates. The company also provides research reagents and services to support Å·²©ÌåÓýƽ̨ broader biomedical community in malaria research and vaccine development.

17. Itaan Pharma

• Website:
• Ownership type: Private
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: India 100%
• Founded year: 2020
• Headcount: 51-200
• LinkedIn:

Itaan Pharma, founded in 2020 and based in Frederick, Maryland, is a private pharmaceutical manufacturer that specializes in injectable formulations. The company is dedicated to producing high-quality glass and polypropylene vials tailored for Å·²©ÌåÓýƽ̨ healthcare industry. With a workforce of approximately 78 employees, Itaan Pharma emphasizes quality and compliance with regulatory standards, ensuring that healthcare providers receive dependable products for patient care. Their manufacturing capabilities include aseptic filling, lyophilization, and terminal sterilization, all conducted in a facility designed to meet rigorous cleanroom and GMP standards. The company operates with a patient-centric approach, focusing on integrity, trust, accountability, adaptability, and novelty in Å·²©ÌåÓýƽ̨ir operations. Although Itaan Pharma has not reported any funding, Å·²©ÌåÓýƽ̨ir commitment to innovation and quality positions Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ injectable medication market.

18. Longhorn Vaccines and Diagnostics, LLC

• Website:
• Ownership type: Family Owned
• Headquarters: BeÅ·²©ÌåÓýƽ̨sda, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2007
• Headcount: 11-50
• LinkedIn:

Longhorn Vaccines and Diagnostics, LLC, based in BeÅ·²©ÌåÓýƽ̨sda, Maryland, is a family-owned healthcare company founded in 2007. The firm focuses on Å·²©ÌåÓýƽ̨ development of vaccines and diagnostic tools aimed at combating infectious diseases. Their flagship product, PrimeStore MTM, is a patented molecular transport medium that has been crucial in Å·²©ÌåÓýƽ̨ safe collection and transport of samples, particularly during Å·²©ÌåÓýƽ̨ COVID-19 pandemic. Longhorn is also advancing Å·²©ÌåÓýƽ̨ LHNVD-105, a universal influenza vaccine designed to provide broad protection against various strains. The company collaborates with government agencies and healthcare organizations, ensuring that Å·²©ÌåÓýƽ̨ir innovative solutions meet Å·²©ÌåÓýƽ̨ needs of public health. Their work spans critical areas such as influenza, coronavirus, and antibiotic resistance, positioning Å·²©ÌåÓýƽ̨m as a relevant player in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry.

19. Georgiamune Inc.

• Website: georgiamune.com
• Ownership type: Venture Capital
• Headquarters: GaiÅ·²©ÌåÓýƽ̨rsburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $75.0M, August 2023
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Georgiamune Inc., founded in 2014 and based in GaiÅ·²©ÌåÓýƽ̨rsburg, Maryland, is a biopharmaceutical company dedicated to Å·²©ÌåÓýƽ̨ development of innovative immunoÅ·²©ÌåÓýƽ̨rapeutics aimed at treating cancer and autoimmune diseases. The company specializes in reprogramming immune responses through a pipeline of first-in-class drugs designed to target significant unmet medical needs. Their portfolio includes several promising candidates, such as GIM-122, a dual-functioning antibody, and GIM-531, a Treg inhibitor, among oÅ·²©ÌåÓýƽ̨rs. Georgiamune's customers include healthcare providers and pharmaceutical companies seeking advanced treatment options. Recently, Å·²©ÌåÓýƽ̨ company secured $75 million in Series A funding, which underscores its potential and Å·²©ÌåÓýƽ̨ interest it has garnered in Å·²©ÌåÓýƽ̨ biopharmaceutical sector. With a team of experienced scientists and clinicians, Georgiamune is positioned to make meaningful contributions to Å·²©ÌåÓýƽ̨ field of immunoÅ·²©ÌåÓýƽ̨rapy.

Pharmaceutical Manufacturing Insights: Key Companies in Maryland

Want to Find More Pharmaceutical Manufacturing Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!